Globalytic
GlobalyticPoliticsConflictsTechScienceHealthBusinessWorld

Globalytic

Independent world coverage — geopolitics, conflicts, science, and health — with AI-assisted editing and verification.

Sections

  • World
  • Politics
  • Conflicts
  • Tech
  • Science
  • Health
  • Business
  • World
  • All news
  • Search

Resources

  • About
  • RSS Feed
  • Search

Summaries and analysis may be AI-assisted. Content is for informational purposes only.

Not professional advice.

© 2026 Globalytic. All rights reserved.

  1. Home
  2. /News
  3. /Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it
HealthAnalysisneutral

Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it

NPR Topics: NewsApr 155 min readOriginal source →
Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it

TL;DR

Many people start GLP-1 medications like Ozempic and Zepbound for diabetes and obesity, but less than 25% continue using them after a year. These drugs are intended for lifelong use, yet a significant number of patients quit.

Key points

  • GLP-1 medications are for diabetes and obesity treatment
  • Intended for lifelong use but many quit
  • Less than 25% of patients continue after one year
  • Research based on insurance claims data
  • Dr. Jaime Almandoz conducted the study

Mentioned in this story

Dr. Jaime AlmandozUniversity of Texas Southwestern Medical Center
GLP-1 medicationsOzempicZepboundJAMA

Why it matters

Understanding patient adherence to GLP-1 medications is crucial for improving treatment outcomes in diabetes and obesity.

Wegovy and Zepbound are arranged for a photograph in California on Thursday, May 8, 2025.
Wegovy and Zepbound are arranged for a photograph in California on Thursday, May 8, 2025.

Wegovy and Zepbound are GLP-1 weight loss treatments. They are available by prescription. JoNel Aleccia/AP

JoNel Aleccia/AP

It's quite common for people to start on GLP-1 drugs like Ozempic and Zepbound, especially as the diabetes and obesity treatments become more ubiquitous. They're designed to treat chronic conditions, so the medicines are intended for lifelong use; yet a high percentage of people who start them also quit.

"We found that fewer than one in four patients remained on a GLP-1 medication after a year," says Dr. Jaime Almandoz, an obesity medicine specialist at the University of Texas Southwestern Medical Center. He looked at insurance claims data in a research letter published in JAMA and found that few patients actually adhere to the drugs for the long term.

Seamless pattern of Injectors / dosing pens for subcutaneous injection of antidiabetic medication or anti-obesity medication on blue background.
Seamless pattern of Injectors / dosing pens for subcutaneous injection of antidiabetic medication or anti-obesity medication on blue background.

Living Better

Advice for trying GLP-1 drugs for weight loss from a doctor who's been there

"Many times obesity treatment is framed as a limited duration intervention that once people get to a weight goal or percentage of weight reduction, that then treatment can be discontinued," Almandoz says. That's outdated thinking, he argues. Patients also stop because of cost, loss of insurance, or side effects.

Interestingly, a separate survey found that most people who quit the drugs said they plan to restart, says Leigh O'Donnell, who analyzes shopper behavior for the market-research firm Kantar. "Seventy-four percent of lapsers say that they are likely or very likely to come back onto a GLP-1," she says. And consumer behavior is shifting very rapidly, as more drugs become available in pill form, at a lower price, and from various online sellers without doctor or insurance approvals. "The barriers to use and reuse are getting so low that it's a little hard to project."

As with many things relating to GLP-1s, consumer behavior is far outpacing research about the effects of their use in different situations. There isn't a lot of research on the health effects of periodic use, though other studies show weight regain after stopping GLP-1s is  faster compared to other diets that focus on behavior changes.

Yet, as O'Donnell notes, on-again-off-again use is already in the cultural zeitgeist. Celebrity use of the drug as a kind of diet aid is "normalizing" cycling behavior, she says.

Social media ads capitalize on that message, too. One online seller, Willow, features younger, fit-looking women in its ads, saying GLP-1s are available even to people who wear a size 4. In one such video, a svelte young woman on a couch asks a doctor, "I'm only looking to lose a couple of pounds, maybe use it temporarily." The doctor assures her it's fine for brief use.

Willow did not respond to requests seeking comment about its marketing. Late last year, Willow declined to modify or discontinue its health-related claims at the Better Business Bureau's request.

The pharmaceutical industry, represented by the trade organization PhRMA, would like to see Medicare rules changed to allow more patients to take the drugs and is pushing for more oversight and reining in of some of the compounding pharmacies that sell GLP-1 drugs directly to consumers.

Experts say one problem is that temporary use could undermine health by diminishing lean muscle mass, every time a person resumes GLP-1s.

On Aging

What science tells us about aging and exercise

As much as 40% of all weight lost on GLP-1s is lean muscle, says Mahmoud Salama Ahmed, a medical chemist at Texas Tech University. While muscle loss is standard with any diet or weight-loss regimen, loss of muscle on GLP-1s can be more dramatic, Ahmed says, causing what's been dubbed "Ozempic face," a bonier, looser-skinned look, where the muscle loss is particularly noticeable.

The problem, he says, is that when people stop the drugs, they tend to gain back fat rapidly. Meanwhile, it is not clear how – or how much – the muscle they lost is also eventually regained. If the patient doesn't work to rebuild that lean mass, Ahmed says, that could lead to sarcopenia – muscle loss – which adversely affects balance, movement, metabolism and can lead to broken or weakened bones.

"We might find some real problems if we are not monitoring the body composition, especially for the older patients," Ahmed says.

However, some say the impacts on muscle might not be so dire; that GLP-1s also improve muscle quality, even if they reduce overall quantity.

When looked at closely, the muscles of those on GLP-1s appear to be healthier — with less fat infiltration and better, stronger fibers, says cardiologist Ian Neeland at Case Western Reserve University.

Step aside BMI, body composition tests are on the rise. Here's what to know
Step aside BMI, body composition tests are on the rise. Here's what to know

Shots - Health News

Step aside BMI, body composition tests are on the rise. Here's what to know

"The key point is not just how much muscle, but how healthy and functional the muscle is," Neeland says, because the goal is always to gain strength, even while losing weight.

Both Neeland and Ahmed say more research is needed on the health effects from short-term use of GLP-1s.

Q&A

What percentage of patients continue using GLP-1 medications after one year?

Fewer than one in four patients remain on GLP-1 medications after a year.

What are GLP-1 medications used for?

GLP-1 medications like Ozempic and Zepbound are used to treat chronic conditions such as diabetes and obesity.

Why do many people quit GLP-1 medications?

Many patients quit GLP-1 medications despite their intended lifelong use, often due to adherence issues.

Who conducted the research on GLP-1 medication adherence?

Dr. Jaime Almandoz, an obesity medicine specialist at the University of Texas Southwestern Medical Center, conducted the research.

People also ask

  • GLP-1 medication adherence rates
  • Why do people stop taking Ozempic?
  • What are the side effects of Zepbound?
  • Long-term use of GLP-1 medications
Load next article

Related Articles

Israeli demolitions levelling towns in south Lebanon, satellite images show
Conflicts

Israeli demolitions levelling towns in south Lebanon, satellite images show

Israeli demolitions have destroyed over 1,400 buildings in southern Lebanon since March 2, as revealed by satellite images. This destruction follows an order from Israel's Defence Minister to accelerate home demolitions near the border.

BBC News·Yesterday·1 min read
Play-off pending? How a draw at the Etihad could set up thrilling finale
World

Play-off pending? How a draw at the Etihad could set up thrilling finale

Arsenal faces Manchester City in a pivotal Premier League clash that could shape the title race.

BBC News·Yesterday·1 min read
Report suggests 'breakthrough' Alzheimer's drugs unlikely to benefit patients
Health

Report suggests 'breakthrough' Alzheimer's drugs unlikely to benefit patients

New analysis questions the effectiveness of Alzheimer's breakthrough drugs.

BBC News·Yesterday·1 min read
Iran war: What is happening on day 48 of the US-Iran conflict?
Conflicts

Iran war: What is happening on day 48 of the US-Iran conflict?

Day 48 of the US-Iran conflict: Negotiations intensify as tensions rise.

Al Jazeera English·Yesterday·1 min read
CEO of bitcoin firm championed by Nigel Farage leaves company
Business

CEO of bitcoin firm championed by Nigel Farage leaves company

The CEO of bitcoin firm Stack BTC, promoted by Nigel Farage, has left the company as it seeks to assure investors of its long-term value. Stack BTC was launched earlier this year and is a rebranded version of Kasei Investment Holdings, which faced liquidation last year.

The Guardian World·Yesterday·1 min read
Ammonia pollution hotspots found in areas of UK with most pig and poultry factory farms
Science

Ammonia pollution hotspots found in areas of UK with most pig and poultry factory farms

New research reveals ammonia pollution hotspots in UK factory farm areas.

The Guardian World·Yesterday·1 min read

More from News

View all →

See every story in News — including breaking news and analysis.

At a glance

  • GLP-1 medications are for diabetes and obesity treatment
  • Intended for lifelong use but many quit
  • Less than 25% of patients continue after one year
  • Research based on insurance claims data
  • Dr. Jaime Almandoz conducted the study

Advertisement

Placeholder